tetano
Editor, Senior Moderator
Vaccine. 2018 Jan 17. pii: S0264-410X(18)30058-6. doi: 10.1016/j.vaccine.2018.01.024. [Epub ahead of print]
[h=1]Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013-2016.[/h] Sugaya N[SUP]1[/SUP], Shinjoh M[SUP]2[/SUP], Nakata Y[SUP]3[/SUP], Tsunematsu K[SUP]4[/SUP], Yamaguchi Y[SUP]5[/SUP], Komiyama O[SUP]6[/SUP], Takahashi H[SUP]7[/SUP], Mitamura K[SUP]8[/SUP], Narabayashi A[SUP]9[/SUP], Takahashi T[SUP]2[/SUP]; Keio Pediatric Influenza Research Group.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age in 2015/16 season. In addition, based on the data obtained during the three seasons from 2013 to 2016, we estimated the three-season VE in preventing influenza illness and hospitalization.
[h=4]METHODS:[/h] Our study was conducted according to a test-negative case-control design (TNCC) and as a case-control study based on influenza rapid diagnostic test results.
[h=4]RESULTS:[/h] During 2015/16 season, the quadrivalent IIV was first used in Japan. The adjusted VE in preventing influenza illness was 49% (95% confidence interval [CI]: 42-55%) against any type of influenza, 57% (95% CI: 50-63%) against influenza A and 34% (95% CI: 23-44%) against influenza B. The 3-season adjusted VE was 45% (95% CI: 41-49%) against influenza virus infection overall (N = 12,888), 51% (95% CI: 47-55%) against influenza A (N = 10,410), and 32% (95% CI: 24-38%) against influenza B (N = 9232). An analysis by age groups showed low or no significant VE in infants or adolescents. By contrast, VE was highest in the young group (1-5 years old) and declined with age thereafter. The 3-season adjusted VE in preventing hospitalization as determined in a case-control study was 52% (95% CI: 42-60%) for influenza A and 28% (95% CI: 4-46%) for influenza B, and by TNCC design, it was 54% (95% CI: 41-65%) for influenza A and 34% (95% CI: 6-54%) for influenza B.
[h=4]CONCLUSION:[/h] We demonstrated not only VE in preventing illness, but also VE in preventing hospitalization based on much larger numbers of children than previous studies.
Copyright ? 2018 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Child; Effectiveness; Hospitalization; Influenza vaccine; Test-negative case control design
PMID: 29361343 DOI: 10.1016/j.vaccine.2018.01.024
[h=1]Three-season effectiveness of inactivated influenza vaccine in preventing influenza illness and hospitalization in children in Japan, 2013-2016.[/h] Sugaya N[SUP]1[/SUP], Shinjoh M[SUP]2[/SUP], Nakata Y[SUP]3[/SUP], Tsunematsu K[SUP]4[/SUP], Yamaguchi Y[SUP]5[/SUP], Komiyama O[SUP]6[/SUP], Takahashi H[SUP]7[/SUP], Mitamura K[SUP]8[/SUP], Narabayashi A[SUP]9[/SUP], Takahashi T[SUP]2[/SUP]; Keio Pediatric Influenza Research Group.
[h=3]Author information[/h]
[h=3]Abstract[/h] [h=4]OBJECTIVES:[/h] We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children 6 months to 15 years of age in 2015/16 season. In addition, based on the data obtained during the three seasons from 2013 to 2016, we estimated the three-season VE in preventing influenza illness and hospitalization.
[h=4]METHODS:[/h] Our study was conducted according to a test-negative case-control design (TNCC) and as a case-control study based on influenza rapid diagnostic test results.
[h=4]RESULTS:[/h] During 2015/16 season, the quadrivalent IIV was first used in Japan. The adjusted VE in preventing influenza illness was 49% (95% confidence interval [CI]: 42-55%) against any type of influenza, 57% (95% CI: 50-63%) against influenza A and 34% (95% CI: 23-44%) against influenza B. The 3-season adjusted VE was 45% (95% CI: 41-49%) against influenza virus infection overall (N = 12,888), 51% (95% CI: 47-55%) against influenza A (N = 10,410), and 32% (95% CI: 24-38%) against influenza B (N = 9232). An analysis by age groups showed low or no significant VE in infants or adolescents. By contrast, VE was highest in the young group (1-5 years old) and declined with age thereafter. The 3-season adjusted VE in preventing hospitalization as determined in a case-control study was 52% (95% CI: 42-60%) for influenza A and 28% (95% CI: 4-46%) for influenza B, and by TNCC design, it was 54% (95% CI: 41-65%) for influenza A and 34% (95% CI: 6-54%) for influenza B.
[h=4]CONCLUSION:[/h] We demonstrated not only VE in preventing illness, but also VE in preventing hospitalization based on much larger numbers of children than previous studies.
Copyright ? 2018 Elsevier Ltd. All rights reserved.
[h=4]KEYWORDS:[/h] Child; Effectiveness; Hospitalization; Influenza vaccine; Test-negative case control design
PMID: 29361343 DOI: 10.1016/j.vaccine.2018.01.024